Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0645

-0.5%

Nov 12 10:07 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Pogeu Mahone

To: Howard Williams who wrote (12450)	9/25/2013 10:08:47 AM
From: NTTG	1 Recommendation Read Replies (2) of 13111

A world of difference between targeted therapy and the red juice...a world of difference. Best bet on that front is to combine a real targeted therapy, with PV-10 as an immune adjunct ....but there is no clinical data on that approach yet. We are talking about patients who are immune compromised already; so the proof will be in the pudding, not the recipe

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next